Evaluate efficacy and safety of short-course and low-dose regimens of fexinidazole in adults with chronic Chagas disease
current phase of drug development
updated 1 Mar 2022
A Phase II Proof of Concept (PoC) study of fexinidazole was initiated in 2014 in Cochabamba and Tarija, Bolivia. The study was interrupted due to safety and tolerability issues. Interim data efficacy and safety analysis suggested potential high efficacy rates of fexinidazole and a decision was made to extend clinical study follow-up to 12 months. Analysis of key efficacy outcomes and safety confirmed the potential high efficacy findings at the lowest dose tested and for all treatment durations, with safety concerns around treatment with high doses tested for more than 14 days. In addition, acceptable safety and tolerability was found at low doses and short treatment durations – taken together, these results warrant further investigation of fexinidazole for Chagas disease.
News & resources
- 4 August 2022 - A phase-2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease, Clinical Infectious Diseases
- 27 March 2019 - A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole, Antimicrobial Agents and Chemotherapy
- 12 August 2014 - New Drug Candidate for Chagas Disease Tested in Patients in Bolivia
Get our latest news, personal stories, research articles, and job opportunities.